US FDA approves Axsome Therapeutics' migraine drug
Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome Therapeutics' AXSM.O migraine treatment, the company said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth